At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ALMS Alumis Inc.
Not Yet Opened 08-21 16:00:00 EDT
24.17
+1.31
+5.73%
盘后23.83
-0.34-1.41%
19:30 EDT
High24.70Low22.21Vol934.81K
Open22.98D1 Closing22.86Amplitude10.88%
Mkt Cap3.12BTradable Cap2.65BTotal Shares129.00M
T/O22.12MT/O Rate0.85%Tradable Shares109.67M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

What Alumis (ALMS)'s Envudeucitinib Phase 3 Data and Deepening Losses Means For Shareholders
Simply Wall St.  ·  08-19
What Alumis (ALMS)'s Envudeucitinib Phase 3 Data and Deepening Losses Means For Shareholders
Alumis Publishes Corporate Deck on Next-Generation TYK2 Inhibitors for Immune-Mediated Diseases
Reuters  ·  08-15
Alumis Publishes Corporate Deck on Next-Generation TYK2 Inhibitors for Immune-Mediated Diseases
Alumis Price Target Maintained with a $25.00/Share by HC Wainwright & Co.
Dow Jones  ·  08-15
Alumis Price Target Maintained with a $25.00/Share by HC Wainwright & Co.
Analysts Offer Insights on Healthcare Companies: Alumis Inc. (ALMS), Cabaletta Bio (CABA) and Capricor Therapeutics (CAPR)
TIPRANKS  ·  08-14
Analysts Offer Insights on Healthcare Companies: Alumis Inc. (ALMS), Cabaletta Bio (CABA) and Capricor Therapeutics (CAPR)
Guggenheim Keeps Their Buy Rating on Alumis Inc. (ALMS)
TIPRANKS  ·  08-14
Guggenheim Keeps Their Buy Rating on Alumis Inc. (ALMS)
Alumis Q2 EPS $(1.11) Misses $(0.71) Estimate, Sales $1.662M Miss $3.468M Estimate
Benzinga Earnings  ·  08-14
Alumis Q2 EPS $(1.11) Misses $(0.71) Estimate, Sales $1.662M Miss $3.468M Estimate
Alumis Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary
Reuters  ·  08-14
Alumis Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary
Alumis Q2 FY26 Net Loss Widens to $142.22 Million; Revenue Falls 37.65% to $1.66 Million
Reuters  ·  08-14
Alumis Q2 FY26 Net Loss Widens to $142.22 Million; Revenue Falls 37.65% to $1.66 Million
Alumis - to Initiate Phase 2 Trial for A-005 in Parkinson's Disease in 1H 2027
THOMSON REUTERS  ·  08-14
Alumis - to Initiate Phase 2 Trial for A-005 in Parkinson's Disease in 1H 2027
Alumis - on Track to Submit Nda for Envudeucitinib in Pso to FDA in Q4 2026
THOMSON REUTERS  ·  08-14
Alumis - on Track to Submit Nda for Envudeucitinib in Pso to FDA in Q4 2026
Press Release: Alumis Reports Second Quarter 2026 Financial Results and Highlights Recent Achievements
Dow Jones  ·  08-14
Press Release: Alumis Reports Second Quarter 2026 Financial Results and Highlights Recent Achievements
Alumis Inc. (ALMS) Receives a Rating Update from a Top Analyst
TIPRANKS  ·  08-13
Alumis Inc. (ALMS) Receives a Rating Update from a Top Analyst
Alumis reports strong Phase 3 data for envudeucitinib
TIPRANKS  ·  08-11
Alumis reports strong Phase 3 data for envudeucitinib
Alumis - Envudeucitinib Shows Consistent Safety Profile with no New Safety Signals in Onward3
THOMSON REUTERS  ·  08-11
Alumis - Envudeucitinib Shows Consistent Safety Profile with no New Safety Signals in Onward3
Alumis - Topline Data from Lumus Phase 2B Trial in Lupus Expected in Q3 2026
THOMSON REUTERS  ·  08-11
Alumis - Topline Data from Lumus Phase 2B Trial in Lupus Expected in Q3 2026
Alumis - to Submit Nda to FDA for Envudeucitinib in Q4 2026
THOMSON REUTERS  ·  08-11
Alumis - to Submit Nda to FDA for Envudeucitinib in Q4 2026
Alumis - 75% of Patients Achieve Pasi 90, 54% Achieve Pasi 100 After 48 Weeks
THOMSON REUTERS  ·  08-11
Alumis - 75% of Patients Achieve Pasi 90, 54% Achieve Pasi 100 After 48 Weeks
Alumis Says Envudeucitinib Hits 54% PASI 100 at 48 Weeks in Onward3 Plaque Psoriasis Extension Study
Reuters  ·  08-11
Alumis Says Envudeucitinib Hits 54% PASI 100 at 48 Weeks in Onward3 Plaque Psoriasis Extension Study
Envudeucitinib Long-term Data Positioned to Set a New Standard for Plaque Psoriasis Treatment, Delivering Highest Reported PASI 100 Skin Clearance Among Oral Therapies
GlobeNewswire  ·  08-11
Envudeucitinib Long-term Data Positioned to Set a New Standard for Plaque Psoriasis Treatment, Delivering Highest Reported PASI 100 Skin Clearance Among Oral Therapies
Alumis: Competitive Pressures and Dosing Drawbacks Support Hold Rating and Unchanged $25 Price Target
TIPRANKS  ·  08-03
Alumis: Competitive Pressures and Dosing Drawbacks Support Hold Rating and Unchanged $25 Price Target

Introduction

Company Name.
Alumis Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Alumis Inc. was incorporated on January 29, 2021, as a Delaware corporation. It is a clinical-stage biopharmaceutical company initially focused on developing two tyrosine kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor designed to achieve maximal target inhibition, and A-005, a CNS-penetrant molecule. The company's mission is to significantly improve patients' lives by replacing broad immunosuppression with targeted therapies.
Issue price:
--